Landscape Capital Management L.L.C. Purchases Shares of 28,194 Insmed, Inc. $INSM

Landscape Capital Management L.L.C. acquired a new position in shares of Insmed, Inc. (NASDAQ:INSM) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 28,194 shares of the biopharmaceutical company’s stock, valued at approximately $4,060,000.

Several other large investors also recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in shares of Insmed by 13.0% during the third quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock valued at $2,870,957,000 after purchasing an additional 2,291,328 shares during the period. Capital International Investors grew its holdings in Insmed by 1.0% during the 3rd quarter. Capital International Investors now owns 7,553,853 shares of the biopharmaceutical company’s stock valued at $1,087,830,000 after purchasing an additional 74,994 shares in the last quarter. Artisan Partners Limited Partnership increased its stake in Insmed by 49.0% during the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock worth $711,076,000 after buying an additional 1,623,342 shares during the period. Invesco Ltd. lifted its holdings in Insmed by 5.7% in the 3rd quarter. Invesco Ltd. now owns 2,003,871 shares of the biopharmaceutical company’s stock worth $288,577,000 after buying an additional 107,538 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Insmed during the second quarter valued at about $194,728,000.

Analyst Ratings Changes

INSM has been the subject of a number of analyst reports. Jefferies Financial Group set a $269.00 price target on Insmed in a report on Wednesday, December 10th. Stifel Nicolaus set a $205.00 price objective on Insmed in a report on Thursday, February 19th. The Goldman Sachs Group upped their target price on Insmed from $225.00 to $258.00 and gave the company a “buy” rating in a research report on Monday, December 15th. UBS Group decreased their price target on shares of Insmed from $223.00 to $215.00 and set a “buy” rating for the company in a research report on Tuesday, January 6th. Finally, Cantor Fitzgerald increased their price objective on shares of Insmed from $216.00 to $230.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Insmed presently has a consensus rating of “Buy” and a consensus target price of $207.52.

Insmed Stock Performance

Shares of INSM traded down $0.19 during midday trading on Friday, hitting $139.34. 203,254 shares of the stock traded hands, compared to its average volume of 2,425,995. The business’s 50 day moving average price is $155.93 and its two-hundred day moving average price is $165.62. The firm has a market capitalization of $30.03 billion, a PE ratio of -21.73 and a beta of 1.13. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $212.75.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). The firm had revenue of $263.84 million during the quarter, compared to analyst estimates of $263.97 million. Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The firm’s revenue was up 152.6% on a year-over-year basis. During the same period last year, the business earned ($1.32) EPS. Equities research analysts predict that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insider Activity

In other Insmed news, CEO William Lewis sold 10,699 shares of Insmed stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $146.03, for a total transaction of $1,562,374.97. Following the sale, the chief executive officer owned 301,185 shares of the company’s stock, valued at $43,982,045.55. The trade was a 3.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Sara Bonstein sold 748 shares of the stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $156.34, for a total value of $116,942.32. Following the completion of the transaction, the chief financial officer directly owned 79,758 shares of the company’s stock, valued at approximately $12,469,365.72. The trade was a 0.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 189,651 shares of company stock worth $31,784,545 over the last ninety days. 3.00% of the stock is owned by company insiders.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.